← All trials
NCT05020535
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2022
- Primary completion
- Dec 1, 2025
- Completion date
- Oct 1, 2026
- First posted
- Aug 25, 2021
- Last posted
- Nov 12, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Johns Hopkins UniversityLead sponsor
- National Institute on Aging (NIA)Collaborator
- University of KentuckyCollaborator
- University of KentuckyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.